Best of ASCO® Toronto 2024: Hematology – Dr. Martina Trinkaus
OR
Co-Chairs
Dr. Aly-Khan Lalani
Dr. Natasha Leighl
Speakers
Dr. Martina Trinkaus
Studies/trials discussed:
- Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
- Daratumumab, Bortezomib, Lenalidomide, and Dexamet hasone for Multiple Myeloma
- A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
- Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).
- Isatuximab, plus lenalidomide, and dexamethasone with weekly bortezomib versus isatuximab plus lenalidomide and dexamethasone in newly diagnosed transplant ineligible Multiple Myeloma. The Benefit (IFM2020-05) study
- Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
- Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study.
- ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.
- Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.
